Skip to main content
Scroll Top
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Home
Alzheimer
15th International Conference on Alzheimer’s Disease & Parkinson’s disease (AD/PD) 2021, virtual conference
Most Viewed Posts
Clear Filters
“Conceiving an innovation is one thing; bringing it to fruition is quite another.” Guillaume Blivet wants to transform the lives of patients with neurological disorders
16 March 2026
REGEnLIFE tests light stimulation on neurodegenerative diseases
23 May 2023
REGEnLIFE: a revolution in the treatment of neurodegenerative diseases
7 February 2025
16 September 2021
15th International Conference on Alzheimer’s Disease & Parkinson’s disease (AD/PD) 2021, virtual conference
15th International Conference on Alzheimer’s Disease & Parkinson’s disease (AD/PD) 2021, virtual conference
Read the article
Guillaume Blivet, Aroa Relano-Gines, Mélanie Wachtel, Jacques Touchon.
Share this article
alzheimer
Oral Communications
Post navigation
Previous post
Light-neuron interaction – from photobiomodulation to optical heating
Next post
Opposite Michel Taube: Patrice Cristofini
Get a Quote